Newer Drug-Eluting Stents May Leave Late Thrombosis Saga Behind – Meta-Analysis
This article was originally published in The Gray Sheet
Executive Summary
In an analysis of about 50,000 patients in 49 different clinical studies, cobalt-chromium everolimus-eluting stents like Abbott’s Xience showed a definitive thrombosis advantage over bare-metal stents at one year and two years following the initial procedure.
You may also be interested in...
Thrombosis Risk In Taxus And Cypher Is Real, TCT Data Shows; Now What?
With a growing consensus coming out of last week's Transcatheter Cardiovascular Therapeutics meeting that first-generation drug-eluting stents (DES) are associated with an increased long-term risk of blood clots, cardiologists are grappling with how use of these blockbuster products might need to be modified
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.